Jung Sungyong, Kim Jayoung
Department of Electrical Engineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Departments of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Bladder (San Franc). 2020 Mar 24;7(1):e40. doi: 10.14440/bladder.2020.813. eCollection 2020.
Molecular biosignatures of altered cellular landscapes and functions have been casually linked with pathological conditions, which imply the promise of biomarkers specific to bladder diseases, such as bladder cancer and other dysfunctions. Urinary biomarkers are particularly attractive due to costs, time, and the minimal and noninvasive efforts acquiring urine. The evolution of omics platforms and bioinformatics for analyzing the genome, epigenome, transcriptome, proteome, lipidome, metabolome, ., have enabled us to develop more sensitive and disease-specific biomarkers. These discoveries broaden our understanding of the complex biology and pathophysiology of bladder diseases, which can ultimately be translated into the clinical setting. In this short review, we will discuss current efforts on identification of promising urinary biomarkers of bladder diseases and their roles in diagnosis and monitoring. With these considerations, we also aim to provide a prospective view of how we can further utilize these bladder biomarkers in developing ideal and smart medical devices that would be applied in the clinic.
细胞景观和功能改变的分子生物标志物已被偶然地与病理状况联系起来,这意味着存在针对膀胱疾病(如膀胱癌和其他功能障碍)的特异性生物标志物的前景。由于成本、时间以及获取尿液所需的最小且非侵入性的努力,尿液生物标志物特别具有吸引力。用于分析基因组、表观基因组、转录组、蛋白质组、脂质组、代谢组等的组学平台和生物信息学的发展,使我们能够开发出更敏感且疾病特异性的生物标志物。这些发现拓宽了我们对膀胱疾病复杂生物学和病理生理学的理解,最终可转化到临床环境中。在这篇简短的综述中,我们将讨论目前在鉴定有前景的膀胱疾病尿液生物标志物方面的努力及其在诊断和监测中的作用。基于这些考虑,我们还旨在前瞻性地探讨如何在开发将应用于临床的理想和智能医疗设备中进一步利用这些膀胱生物标志物。